The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First‐Line Hypomethylating Agents Fail

BACKGROUND. Although hypomethylating agents (HMAs) are effective and approved therapies for patients with myelodysplastic syndromes (MDS), many patients do not benefit from treatment, and nearly all ultimately stop responding to HMAs. The incidence and cost burden of HMA failure are unknown yet need...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Cogle, Christopher R., Kurtin, Sandra E., Bentley, Tanya G. K., Broder, Michael S., Chang, Eunice, Megaffin, Scott, Fruchtman, Steven, Petrone, Michael E., Mukherjee, Sudipto
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2017
Teme:
Academia‐Pharma Intersect
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388372/
https://ncbi.nlm.nih.gov/pubmed/28283585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0211
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items